Full Press Release Details
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma.
IDYA
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Price reaction · baseline $23.81 (2021-11-26 close) · 1 other IDYA headline(s) in the window, move may be shared
day 0 close
-6.2%
day 1 · peak
-7.6%
day 3
-5.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma